XTX Topco Ltd Reduces Stake in Exelixis, Inc. $EXEL

XTX Topco Ltd decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 30.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 28,754 shares of the biotechnology company’s stock after selling 12,312 shares during the quarter. XTX Topco Ltd’s holdings in Exelixis were worth $1,267,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. Belpointe Asset Management LLC acquired a new position in shares of Exelixis in the first quarter valued at approximately $572,000. Fox Run Management L.L.C. acquired a new stake in shares of Exelixis in the 2nd quarter worth approximately $321,000. D.A. Davidson & CO. purchased a new position in shares of Exelixis in the second quarter valued at $212,000. Fortis Capital Advisors LLC acquired a new position in Exelixis during the first quarter worth about $572,000. Finally, Ellsworth Advisors LLC acquired a new stake in Exelixis during the 1st quarter valued at $3,589,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Exelixis

In other news, Director Mary C. Beckerle sold 24,622 shares of Exelixis stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $41.93, for a total value of $1,032,400.46. Following the transaction, the director directly owned 21,380 shares of the company’s stock, valued at $896,463.40. The trade was a 53.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Patrick J. Haley sold 34,187 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $41.88, for a total value of $1,431,751.56. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 245,235 shares of company stock valued at $10,490,600. 2.82% of the stock is owned by company insiders.

Exelixis Stock Down 0.2%

Shares of EXEL opened at $44.12 on Friday. Exelixis, Inc. has a fifty-two week low of $31.90 and a fifty-two week high of $49.62. The company’s fifty day moving average is $40.24 and its two-hundred day moving average is $40.90. The firm has a market cap of $11.83 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 0.79 and a beta of 0.32.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $597.76 million during the quarter, compared to the consensus estimate of $590.04 million. During the same period in the prior year, the firm posted $0.47 EPS. The business’s revenue for the quarter was up 10.8% on a year-over-year basis. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on EXEL shares. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a research note on Wednesday, October 8th. Stifel Nicolaus set a $43.00 price target on shares of Exelixis in a report on Wednesday, November 5th. UBS Group upped their price objective on shares of Exelixis from $35.00 to $40.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. HC Wainwright lifted their target price on shares of Exelixis from $46.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Barclays increased their price target on Exelixis from $40.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $45.45.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.